Vimizim Approval History
FDA Approved: Yes (First approved February 14, 2014)
Brand name: Vimizim
Generic name: elosufase alfa
Dosage form: Injection
Company: BioMarin Pharmaceutical Inc.
Treatment for: Mucopolysaccharidosis Type IVA
Vimizim (elosufase alfa) is an enzyme replacement therapy for patients with Mucopolysaccharidosis Type IVA (Morquio A syndrome).
Development History and FDA Approval Process for Vimizim
|Feb 16, 2014||FDA Approves Vimizim to Treat Mucopolysaccharidosis Type IVA|
|Nov 20, 2013||FDA Advisory Committee Recommends Approval of Vimizim for Morquio A Syndrome|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.